Key result
In a meta-analysis of 206,632 patients with 7,108 strokes, angiotensin II-decreasing drugs were associated with a significantly higher risk of stroke compared to angiotensin II-increasing drugs.
Why the study?
Do angiotensin II-decreasing antihypertensive drugs increase the risk of stroke compared to angiotensin II-increasing drugs in patients without heart failure?
Meta-Analysis (n=206,632)
Do angiotensin II-decreasing antihypertensive drugs increase the risk of stroke compared to angiotensin II-increasing drugs in patients without heart failure?
Angiotensin II-decreasing antihypertensive drugs may be less protective against stroke than angiotensin II-increasing drugs, an effect not fully explained by differences in blood pressure reduction.
Answers are grounded in this paper and cite their sources.
Angiotensin II-decreasing antihypertensives may raise stroke risk versus increasing agents; challenges class equivalence beyond BP reduction.
BACKGROUND: Stroke prevention by antihypertensive therapy is believed to be related to the fall in blood pressure (BP). Experimental data have documented that activation of non-AT1 receptors of angiotensin II may exert anti-ischaemic mechanisms in the brain. The present meta-analysis of various randomized clinical trials attempts to relate stroke risk to angiotensin II formation during antihypertensive therapy. METHODS: Primary and secondary stroke prevention was examined in 26 prospective, randomized clinical trials including 206,632 patients without heart failure, in whom a total of 7,108 strokes occurred. The trials were selected because a difference in angiotensin II generation was expected between the two treatment arms on the basis of the drugs' pharmacodynamic effects, and allowed 36 evaluations of the relative risk of stroke. FINDINGS: In placebo-controlled trials, stroke risk was significantly higher with angiotensin II-decreasing than increasing drugs, but systolic BP decreased less in the former. Compared with an active therapy having a neutral effect on angiotensin II formation, stroke risk was also higher with angiotensin-decreasing drugs than with angiotensin-increasing drugs, whereas BP decrease was comparable with both drug classes. When angiotensin II-decreasing drugs were directly compared with angiotensin II-increasing drugs in the same trials, stroke risk was significantly increased. On-treatment systolic BP was minimally and significantly higher with angiotensin II-decreasing drugs, but not large enough to explain the excess in stroke risk. CONCLUSION: Within the limitations of the methodology, our meta-analysis supports the hypothesis that angiotensin II-decreasing drugs are less stroke protective than angiotensin II-increasing drugs, although this difference is not entirely explained by their smaller BP-lowering effect.
No takes yet. Share an insight, caveat, or question.
Boutitie et al. (2007) conducted a meta-analysis in Stroke prevention (n=206,632). Angiotensin II-decreasing drugs vs. Angiotensin II-increasing drugs, placebo, or neutral active therapy was evaluated on Stroke. In a meta-analysis of 206,632 patients with 7,108 strokes, angiotensin II-decreasing drugs were associated with a significantly higher risk of stroke compared to angiotensin II-increasing drugs.
Synapse has enriched 10 related papers. Consider them for comparative context: